Elisabeth Crönert-Bendell
Corporate Officer/Principal bei RHYTHM PHARMACEUTICALS, INC.
Profil
Elisabeth Crönert-Bendell is currently the Senior Vice President & Head-Strategy at Rhythm Pharmaceuticals, Inc. She previously worked as a Senior Vice President at Sanofi and as the Head-Neuroscience Business Franchise at Kyowa Kirin International Plc.
Dr. Crönert-Bendell holds an MBA from INSEAD.
Aktive Positionen von Elisabeth Crönert-Bendell
Unternehmen | Position | Beginn |
---|---|---|
RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.04.2021 |
Ehemalige bekannte Positionen von Elisabeth Crönert-Bendell
Unternehmen | Position | Ende |
---|---|---|
SANOFI | Corporate Officer/Principal | - |
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Elisabeth Crönert-Bendell
INSEAD | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SANOFI | Commercial Services |
RHYTHM PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |